ArticleEye (London, England)2025
Photobiomodulation-induced choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate age-related macular degeneration: a promising therapeutic approach with short-term results.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Tear biomarker changes and ocular surface recovery with low-level light therapy after cataract surgery: a double-masked randomized controlled clinical trial.Scientific reports · 2026Trial
- Photobiomodulation for Photoreceptor Rescue in Retinal Disease: Mitochondrial, Redox, Vascular, and Translational Perspectives-A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- Response to: 'Comment on: 'Photobiomodulation-induced choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate age-related macular degeneration: a promising therapeutic approach with short-term results".Eye (London, England) · 2026Article
- Comment on: 'Photobiomodulation-induced choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate age-related macular degeneration: a promising therapeutic approach with short-term results'.Eye (London, England) · 2026Article
- Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effects of photobiomodulation (PBM) on choriocapillaris (CC) perfusion and drusen volume in patients with intermediate age-related macular degeneration (AMD).
methodsIn this retrospective pilot study, 30 patients receiving PBM therapy and 30 age-matched controls were analysed. Treatment consisted of 8 sessions over 4 weeks using the EYE-LIGHT® device. Best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), mean drusen volume (MDV), and CC flow deficit percentage (FD%) were evaluated at baseline and 2-month follow-up.
resultsThe PBM group showed significant improvements in BCVA (Δ +3.2 ± 1.4 letters, p = 0.042), reduction in drusen volume (Δ -0.003 ± 0.001 mm³, p = 0.028), and decrease in choriocapillaris FD% (Δ -3.1 ± 1.4%, p = 0.024), while no significant changes were observed in the control group. Changes in choriocapillaris FD% correlated with BCVA improvement (r = -0.54, p = 0.002) and drusen volume reduction (r = 0.35, p = 0.042).
conclusionsPBM therapy induces significant choriocapillaris remodelling in intermediate AMD, associated with functional improvement and drusen volume reduction. These findings suggest a potential therapeutic role of PBM in modulating choroidal perfusion in AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.